|
GB9518953D0
(en)
|
1995-09-15 |
1995-11-15 |
Pfizer Ltd |
Pharmaceutical formulations
|
|
WO2001077073A1
(en)
|
2000-04-06 |
2001-10-18 |
Merck Frosst Canada & Co. |
Cathepsin cysteine protease inhibitors
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
WO2007119214A2
(en)
|
2006-04-13 |
2007-10-25 |
Actelion Pharmaceuticals Ltd |
Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
|
|
US8242271B2
(en)
|
2007-06-04 |
2012-08-14 |
Avila Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
|
PE20090606A1
(es)
|
2007-08-20 |
2009-06-17 |
Glaxo Group Ltd |
Nuevos inhibidores de catepsina c y uso
|
|
PE20091843A1
(es)
|
2008-04-18 |
2010-01-07 |
Glaxo Group Ltd |
Inhibidores de catepsina c
|
|
TW201002318A
(en)
|
2008-04-18 |
2010-01-16 |
Glaxo Group Ltd |
Cathepsin C inhibitors
|
|
WO2009129370A1
(en)
|
2008-04-18 |
2009-10-22 |
Glaxo Group Limited |
Cathepsin c inhibitors
|
|
US20120309820A1
(en)
|
2011-06-04 |
2012-12-06 |
Jb Therapeutics Inc. |
Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
|
|
EP2565186A1
(en)
|
2011-09-02 |
2013-03-06 |
Hybrigenics S.A. |
Selective and reversible inhibitors of ubiquitin specific protease 7
|
|
CA2918242C
(en)
|
2013-07-31 |
2022-06-21 |
Merck Patent Gmbh |
Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
|
|
US9963444B2
(en)
|
2014-05-19 |
2018-05-08 |
Northeastern University |
N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
|
|
WO2015183987A1
(en)
|
2014-05-27 |
2015-12-03 |
Pharmakea, Inc. |
Compositions and methods of delivery of deubiquitinase inhibitors
|
|
WO2016019237A2
(en)
|
2014-07-31 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
CA2960277A1
(en)
*
|
2014-09-10 |
2016-03-17 |
Epizyme, Inc. |
Substituted pyrrolidine carboxamide compounds
|
|
GB201416754D0
(en)
*
|
2014-09-23 |
2014-11-05 |
Mission Therapeutics Ltd |
Novel compounds
|
|
MX373656B
(es)
*
|
2015-03-30 |
2020-04-02 |
Mission Therapeutics Ltd |
Compuestos de 1-ciano-pirrolidina como inhibidores de las enzimas desubiquitinantes, como la hidrolasa 30 de la c-terminal de la ubiquitina (usp30), y el uso de los mismos en el tratamiento de condiciones de disfunción mitocondrial y tratamiento de cancér.
|
|
US10669234B2
(en)
|
2015-07-14 |
2020-06-02 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
GB201521109D0
(en)
|
2015-11-30 |
2016-01-13 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201522267D0
(en)
|
2015-12-17 |
2016-02-03 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201522768D0
(en)
|
2015-12-23 |
2016-02-03 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201602854D0
(en)
|
2016-02-18 |
2016-04-06 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201603779D0
(en)
|
2016-03-04 |
2016-04-20 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201604647D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201604638D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
JP6959252B2
(ja)
*
|
2016-03-24 |
2021-11-02 |
ミッション セラピューティクス リミティド |
Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
|
|
ES2850349T3
(es)
|
2016-09-27 |
2021-08-27 |
Mission Therapeutics Ltd |
Derivados de cianopirrolidina con actividad como inhibidores de USP30
|
|
GB201616511D0
(en)
|
2016-09-29 |
2016-11-16 |
Mission Therapeutics Limited |
Novel compounds
|
|
GB201616627D0
(en)
|
2016-09-30 |
2016-11-16 |
Mission Therapeutics Limited |
Novel compounds
|
|
TWI771327B
(zh)
|
2016-10-05 |
2022-07-21 |
英商使命醫療公司 |
新穎化合物
|
|
US10968172B2
(en)
|
2017-05-15 |
2021-04-06 |
Mitobridge, Inc. |
USP30 inhibitors
|
|
GB201708652D0
(en)
|
2017-05-31 |
2017-07-12 |
Mission Therapeutics Ltd |
Novel compounds and uses
|
|
GB2563595B
(en)
|
2017-06-19 |
2020-04-15 |
Edwards Ltd |
Twin-shaft pumps
|
|
BR112020003725A2
(pt)
|
2017-10-06 |
2020-11-03 |
Forma Therapeutics, Inc. |
inibição da peptidase 30 específica de ubiquitina
|
|
GB2571731A
(en)
|
2018-03-06 |
2019-09-11 |
Mission Therapeutics Ltd |
Novel compounds and uses
|
|
JP7449242B2
(ja)
|
2018-05-17 |
2024-03-13 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
|
|
JP7434285B2
(ja)
|
2018-08-14 |
2024-02-20 |
アムジエン・インコーポレーテツド |
Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用
|
|
LT3860989T
(lt)
|
2018-10-05 |
2023-06-12 |
Forma Therapeutics, Inc. |
Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
|
|
IL298526A
(en)
*
|
2020-05-28 |
2023-01-01 |
Mission Therapeutics Ltd |
N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
|